Menus Subscribe Search

Genes Are Us

pencil-dna

(Photo: Lightspring/Shutterstock)

The FDA Is Not Anti-Genetics

• January 17, 2014 • 12:00 PM

(Photo: Lightspring/Shutterstock)

Despite the recent crackdown on 23andMe, the FDA is engaging with fast-moving biotechnology advances. However, there’s still much work to be done.

When the FDA shut down biotech company 23andMe’s direct-to-consumer Personal Genome Service, many in the biotech community worried that the FDA was risking the survival of a nascent industry that would revolutionize medical care with new genetic technologies. But lost in the story about 23andMe was the news that the FDA had just issued its very first approval for a next-generation DNA analysis machine, clearly signaling that the agency recognizes the growing significance of genetic testing in medicine.

The FDA approved a machine called the MiSeqDx, “the first FDA-regulated test system that allows laboratories to develop and validate sequencing of any part of a patient’s genome.” For a few hundred dollars, this little machine can analyze an amount of DNA in 24 hours that, 10 years ago, would have taken a dozen machines two weeks and cost nearly a million dollars. The rate of improvement in our technical capacity to read out DNA has been stunningly rapid, outpacing even the expectations of Moore’s Law, the gold standard for progress in the computer industry. Biomedical researchers can now consider ways to bring DNA analysis into the clinic that would have been impossible before. Rather than testing for mutations in one gene at a time, and in only very specific groups of patients, it’s becoming feasible to scan much larger portions of a patient’s DNA as part of a routine health assessment for everyone. What’s happening in medical genetics is the equivalent of having the operating costs of a private jet suddenly drop to those of a Honda Civic—in which case you’d probably start considering previously unthinkable destinations for not only the annual family vacation, but for three-day weekends as well.

In a report issued last fall (PDF), the FDA laid out its view of the regulatory challenges posed by personalized genetic medicine. At issue is the idea that with cheap, accessible DNA analysis, medical care can be personalized to match each person’s genetic makeup. Cancer diagnoses, rather than being based on abnormalities that are visible under a microscope, would instead be classified more effectively by their underlying genetic mutations. The typical trial-and-error approach to find the right drug for a patient suffering from depression would give way to a genetic test that would indicate the best drug.

Does the FDA need to protect you from information about your genome, especially if some of that information is potentially unreliable? Or should anyone be able to buy a tentative analysis of their genome based on the latest research?

It sounds great in principle, but the result is a major headache for the FDA, because modern genetic medicine is demolishing regulatory concepts and categories that the agency has long used to ensure that drugs and diagnostics are safe and effective.

Take genetic tests for instance. The two primary criteria the FDA uses to evaluate diagnostics are analytical validity and clinical validity. As the FDA report describes them, “analytical validity refers to how well the test measures what it is supposed to measure, whereas clinical validity looks at how well the test predicts who has or does not have a disease or condition for which it is being tested.” A typical diagnostic test is required to be both analytically and clinically valid, but for large-scale genetic tests this doesn’t make sense. Tests that analyze hundreds or thousands of regions of your DNA at once can be analytically valid—that is, they accurately determine the identity of mutations in your genome—but the clinical validity will vary with the individual mutation, depending on whether that mutation has a discernible effect. Furthermore, clinical validity for any one mutation will often be in flux, as new research clarifies the role of poorly understood mutations.

Another challenge with personalization is that a drug and a diagnostic test are more likely to be paired in their development. Some drugs, like the cystic fibrosis drug Kalydeco, are deliberately targeted only at patients with a specific mutation. Pairing genetic tests with therapeutics makes it difficult to track down the source of problems when something doesn’t work. As the FDA report notes, “An adverse event associated with the use of a therapeutic product may have arisen as a result of failure of the test to identify the optimal subset of patients due to design deficiencies, manufacturing deficiencies, or operator error.”

To respond to these challenges, the FDA report describes the changes you’d expect from a large and complex government agency tasked with keeping up with a large and complex industry. There are restructurings, efforts to increase communication and coordination among different agency centers, and committees to rethink the process by which some new treatments and diagnostics are approved.

WHILE THE FDA MAY be making an admirable effort to confront the issues raised in the report, the authors ignored the elephant in the room: the wild frontier of direct-to-consumer genetic testing, represented by 23andMe. Consumer-oriented genome services undermine one of the biggest regulatory concepts that the FDA depends on: whether or not something counts as a medical diagnostic device. Does the FDA need to protect you from information about your genome, especially if some of that information is potentially unreliable? Or should anyone be able to buy a tentative analysis of their genome based on the latest research?

This is where medical genetics shades into recreational genetics. It doesn’t help that these services are often advertised with the dubious claim that they will empower you to take your health into your own hands. As a group of researchers, physicians, and health policy experts noted in a recent commentary, “there is little evidence to support the basic premise implied by the empowerment rhetoric—namely that individuals will use genomic risk information to adopt a healthier lifestyle and, thus, reduce their risk for chronic diseases.”

Even if a personal genome analysis is not useful yet, it is hard to make the case that we should be barred from it. These services feed our curiosity about ourselves, and they are an opportunity to educate consumers about genetics. Of course our genetics are inextricably tied up with our health, which means that direct-to-consumer genetic services will always threaten to impinge on the FDA’s territory. How it should respond is an issue not yet resolved.

Michael White
Michael White is a systems biologist at the Department of Genetics and the Center for Genome Sciences and Systems Biology at the Washington University School of Medicine in St. Louis, where he studies how DNA encodes information for gene regulation. He co-founded the online science pub The Finch and Pea. Follow him on Twitter @genologos.

More From Michael White

A weekly roundup of the best of Pacific Standard and PSmag.com, delivered straight to your inbox.

Recent Posts

August 22 • 4:00 PM

The Invention of the Illegal Immigrant

It’s only fairly recently that we started to use the term that’s so popular right now.



August 22 • 2:00 PM

What Can U.S. Health Care Learn From the Ebola Outbreak?

A conversation with Jeanine Thomas, patient advocate, active member of ProPublica’s Patient Harm Facebook Community, and founder and president of the MRSA Survivors Network.


August 22 • 1:22 PM

Two Executions and the Unity of Mourning

The recent deaths of Michael Brown and James Foley, while worlds apart, are both emblematic of the necessity for all of us to fight to uphold the sanctity of human dignity and its enduring story.


August 22 • 10:00 AM

Turbo Paul: Art Thief Turned Art Crime Ombudsman

There’s art theft, there’s law enforcement, and, somewhere in between, there’s Turbo Paul.


August 22 • 8:00 AM

When Climate Change Denial Refutes Itself

The world is warming—and record-cold winters are just another symptom.


August 22 • 6:17 AM

The Impossibility of the Night Shift

Many night workers get “shift-work sleep disorder.” And no one knows how to treat it.


August 22 • 6:00 AM

Long Live Short Novels

Christopher Beha’s Arts & Entertainments comes in at less than 300 pages long, which—along with a plot centered on a sex-tape scandal—makes it a uniquely efficient pleasure.


August 22 • 4:00 AM

Why ‘Nature Versus Nurture’ Often Doesn’t Matter

Sometimes it just doesn’t make any sense to try to separate the social and the biological.


August 21 • 4:00 PM

Julie Chen Explains Why She Underwent Westernizing Surgery

The CBS news anchor and television personality’s story proves that cosmetic surgeries aren’t always vanity projects, even if they’re usually portrayed that way.


August 21 • 2:37 PM

How the Brains of Risk-Taking Teens Work

There’s heightened functional connectivity between the brain’s emotion regulator and reason center, according to a recent neuroscience paper.


August 21 • 2:00 PM

Cracking Down on the Use of Restraints in Schools

Federal investigators found that children at two Virginia schools were being regularly pinned down or isolated and that their education was suffering as a result.


August 21 • 12:00 PM

What Makes You So Smart, School Principal?

Noah Davis talks to Evan Glazer about why kids aren’t getting smarter and what his school’s doing in order to change that.



August 21 • 10:00 AM

Why My Neighbors Still Use Dial-Up Internet

It’s not because they want to. It’s because they have no other choice.


August 21 • 8:15 AM

When Mothers Sing, Premature Babies Thrive

Moms willing to serenade pre-term infants help their babies—and themselves.


August 21 • 8:00 AM

To Fight the Obesity Epidemic Americans Will Have to First Recognize That They’re Obese

There is a void in the medical community’s understanding of how families see themselves and understand their weight.


August 21 • 6:33 AM

One Toxic Boss Can Poison the Whole Workplace

Office leaders who bully even just one member of their team harm everyone.


August 21 • 6:00 AM

The Fox News Effect

Whatever you think of its approach, Fox News has created a more conservative Congress and a more polarized electorate, according to a series of recent studies.


August 21 • 4:00 AM

Do Children Help Care for the Family Pet?

Or does mom do it all?


August 20 • 4:00 PM

Why Can’t Conservatives See the Benefits of Affordable Child Care?

Private programs might do a better job of watching our kids than state-run programs, but they’re not accessible to everyone.


August 20 • 2:00 PM

Oil and Gas Companies Are Illegally Using Diesel Fuel in Hundreds of Fracking Operations

An analysis by an environmental group finds hundreds of cases in which drillers used diesel fuel without obtaining permits and sometimes altered records disclosing they had done so.


August 20 • 12:00 PM

The Mystery of Britain’s Alien Big Cats

In a nation where the biggest carnivorous predator is a badger, why are there so many reported sightings of large cats?


August 20 • 10:00 AM

Death Row in Arizona: Where Human Experimentation Is the Rule, Not the Exception

Recent reports show that chemical roulette is the state’s M.O.


August 20 • 9:51 AM

Diversity Is in the Eye of the Beholder

Perception of group diversity depends on the race of the observer and the extent to which they worry about discrimination.


Follow us


The Impossibility of the Night Shift

Many night workers get “shift-work sleep disorder.” And no one knows how to treat it.

How the Brains of Risk-Taking Teens Work

There's heightened functional connectivity between the brain's emotion regulator and reason center, according to a recent neuroscience paper.

When Mothers Sing, Premature Babies Thrive

Moms willing to serenade pre-term infants help their babies—and themselves.

One Toxic Boss Can Poison the Whole Workplace

Office leaders who bully even just one member of their team harm everyone.

Diversity Is in the Eye of the Beholder

Perception of group diversity depends on the race of the observer and the extent to which they worry about discrimination.

The Big One

One in two full-time American fast-food workers' families are enrolled in public assistance programs, at a cost of $7 billion per year. July/August 2014 fast-food-big-one
Subscribe Now

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.